首页|厄贝沙坦联合霉酚酸酯治疗狼疮性肾炎的疗效及对尿液生物学标记物的影响

厄贝沙坦联合霉酚酸酯治疗狼疮性肾炎的疗效及对尿液生物学标记物的影响

扫码查看
目的 探讨厄贝沙坦联合霉酚酸酯治疗狼疮性肾炎(LN)的疗效及对尿液生物学标记物的影响.方法 选择2016年1月至2018年12月在南京医科大学附属无锡第二医院肾内科治疗的89例LN患者,按随机数表法为对照组(43例)和试验组(46例).两组均给予标准激素治疗,对照组在此基础上使用厄贝沙坦联合环磷酰胺治疗,试验组在对照组基础上使用霉酚酸酯联合厄贝沙坦治疗.两组均持续治疗6个月,比较治疗效果及尿液生物学标记物水平.结果 试验组治疗总有效率高于对照组,P<0.05.治疗后,试验组尿液生物学标记物、24 h尿蛋白定量、Scr、BUN水平均低于对照组,P<0.05.两组不良反应发生率对比,P>0.05.结论 厄贝沙坦联合霉酚酸酯可提高LN治疗效果,降低尿液生物学标记物水平,且用药安全性好.
Effect ofIrbesartan Combined with Mycophenolate Mofetil on Lupus Nephritis And its Effect on Urine Biomarkers
Objective:To Objective To investigate the efficacy of irbesartan combined with mycophenolate mofetil in the treatment of lupus nephritis(LN)and its influence on urinary biomarkers.Methods:From January 2016 to De-cember 2018,89 patients with LN who were treated in the Department of Nephrology,Wuxi Second Hospital affili-ated to Nanjing Medical University were randomly divided into control group(43 cases)and experimental group(46 cases).Both groups were given standard hormone therapy,the control group was treated with irbesartan combined with cyclophosphamide,and the experimental group was treated with mycophenolate mofetil combined with irbe-sartan on the basis of the control group.Both groups continued to be treated for 6 months,and the therapeutic effect and the level of urinary biomarkers were compared.Results:The total effective rate in the experimental group was higher than that in the control group,P<0.05.After treatment,the urine biomarkers、24-hour urine protein quantification、Scr and BUN levels in the experimental group were lower than those in the control group,P<0.05.The incidence of adverse reactions between the two groups was compared,P>0.05.Conclusion:Irbesartan combined with mycophenolate mofetil can improve the therapeutic effect of LN,reduce the level of urinary biomark-ers,and have good drug safety.

IrbesartanMycophenolate mofetilLupus nephritisUrine biological marker

周瑛

展开 >

南京医科大学附属无锡第二医院肾内科,江苏无锡 214002

厄贝沙坦 霉酚酸酯 狼疮性肾炎 尿液生物学标记物

2024

生命科学仪器
北京市北分仪器技术公司

生命科学仪器

影响因子:0.305
ISSN:1671-7929
年,卷(期):2024.22(1)
  • 10